SMT D001 (Sialorrhoea)
Development Status
SMT D001 has successfully completed a Phase I study in healthy volunteers that demonstarated a 40% reduction in stimulated saliva production. In May 2009, Summit entered into a licensing agreement with the Taiwanese based company Orient Pharma. Click here to read the Press Release (PDF 80 KB).
Under the terms of the agreement, Orient will fund the development of a novel buccal formulation of SMT D001 using its proprietary drug delivery technology at a new FDA approved manufacturing plant in Taiwan. The new buccal formulation will help deliver SMT D001 directly to the affected areas in patients with the aim of increasing its efficacy in reducing excessive drooling and improving patient compliance.
